4Filed May 10, 8:00 PM ET
Odyssey Therapeutics (ODTX) CEO Gary Glick Receives Award, Converts Shares
$ODTX · Odyssey Therapeutics, Inc.Research Summary
AI-generated summary of this SEC filing
Odyssey Therapeutics (ODTX) CEO Gary Glick Receives Award, Converts Shares
What Happened
Gary D. Glick, President and Chief Executive Officer of Odyssey Therapeutics (ODTX), received a grant of 884,450 derivative shares on 2026-05-07 (reported 2026-05-11) at $0.00. On 2026-05-11 he recorded conversions of derivative securities: an acquisition of 27,386 common shares and dispositions of 100,000 and 166,116 derivative shares (these disposition entries are noted as "Derivative" on the Form 4). The award shows a $0.00 per-share price (no cash paid); the conversion/disposition entries list N/A prices.
Key Details
- Transaction dates: grant/award 2026-05-07 (reported 2026-05-11); conversions recorded 2026-05-11.
- Prices/values: Awarded 884,450 derivative shares @ $0.00 (total cash paid = $0); conversion/disposition entries shown with N/A prices.
- Shares reported converted/disposed on 5/11: 27,386 shares acquired; 100,000 and 166,116 shares disposed (derivative). Total disposed = 266,116.
- Shares owned after the transactions: not specified in the provided summary.
- Filing timeliness: Form filed 2026-05-11 for transactions with a period ending 2026-05-07 (no indication of a late filing).
- Remarks: Reporting person listed as President and Chief Executive Officer.
Context
- The filing’s footnotes explain these were conversions of preferred/derivative securities in connection with the issuer’s IPO: Series C and Series D preferred shares converted into common stock on a 1-for-9.7170 basis for no additional consideration (footnotes F1–F3). A 1-for-9.7170 reverse split was also given effect prior to the IPO.
- The 884,450 award appears to be subject to time-based vesting: an option/award vests in 48 equal monthly installments with the first installment scheduled to vest on June 7, 2026 (footnote F4).
- These entries reflect corporate/IPO-related conversions and an awarded derivative position rather than open-market purchases or cash sales; they should be read as capital-structure/compensation actions rather than a straightforward buy/sell signal.